Congress is considering a new bill that, in theory, would boost low-income patients’ - especially Latinos’ - access to ...

A group of House lawmakers is urging HHS to scrap or revise its proposed 340B rebate model pilot program, warning the model could dismantle the original intent of the program and harm safety-net ...

The hospital lobby wants the Trump administration to investigate Johnson & Johnson, Eli Lilly, Sanofi, Novartis and Bristol ...

For-profit drug manufacturers want to change how the 340B Drug Pricing Program works, but going from upfront savings to back-end rebates will kill nonprofit health providers.

A bipartisan group of lawmakers has sent a letter to the Department of Health and Human Services, asking the agency to cancel ...

More than 160 lawmakers have urged the Trump administration to abandon a newly announced pilot program that would allow ...

The pilot is a significant departure from the current model, which gives hospitals upfront discounts for some drugs. The program has proved a flash point between drugmakers and providers, as ...

HRSA is piloting a 340B rebate model similar to one that it just fought against. As the agency dips its toes into the 340B debate, hospital groups express concerns about the potential for cash flow ...

Your recent story, 340B Pricing Program: Serving Vulnerable Patients or Enriching Hospitals?, contains several factual errors and contextual inaccuracies and leaves unchallenged specious statements by ...

The pharmaceuticals lobby shored up its campaign against increasing use of the 340B Drug Discount Program with a new analysis estimating its broader use pulled $6.5 billion in rebates away from the ...

The 100% woman-owned consulting firm partners with healthcare organizations to help them understand, implement, and optimize ...